Business Update

AstraZeneca announces Recentin as trademark name for cancer treatment AZD2171

Published in Health Business Week, February 9th, 2007

AstraZeneca announced Recentin as the global trademark for AZD2171, its oral, highly potent and selective vascular endothelial growth factor (VEGF) signaling inhibitor. AZD2171 is currently in phase II/III development for advanced non-small cell lung cancer (NSCLC) and advanced colorectal cancer (CRC) - as well as a wide-ranging signal search program in other tumors.

"The announcement of a brand name represents a key milestone in the development of AZD2171," commented Ian Triggs, Global Brand Strategy director for AZD2171.

Nick Botwood, Global Medical director for AZD2171, added, "Preclinical data shows this compound is a potent suppressor of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week

Source: Health Business Week (2007-02-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry